Navigation Links
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Date:12/7/2009

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

SOURCE AETERNA ZENTARIS INC.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014   SunTrust Robinson Humphrey (STRH) ... to its equity research team in biotechnology and ... in equity research demonstrates our commitment to providing ... enhance their investment decision making," said Biff ... continue to make significant investments in differentiated content ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... Scientists, researchers, and technologists will converge ... Damage 2014 symposium. Marking its 46th year, the ... run 14-17 September. The event is sponsored by ... , The premier conference for basic and applied issues ... materials will engage researchers and engineers from numerous industries ...
(Date:8/28/2014)... Earlier this month, a report was created by ... Air Force on the performance of vehicles using an ... of fuel made from mustard seeds, offered great potential ... Eco friendly future. In fact, every branch of the ... of foreign oil over the next few years. They ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... ABBOTT PARK, Ill., Sept. 17 The board of directors of ... 40 cents per share. , , This marks the ... cash dividend is payable Nov. 15, 2009, to shareholders of record at the ... has increased its dividend payout for 37 consecutive years - including an 11 ...
... , BOULDER, Colo., Sept. 17 ... awarded two Phase I Small Business Innovation Research (SBIR) grants ... Infectious Diseases (NIAID) of The National Institutes of Health (NIH). ... toxicology and pharmacology studies of the company,s proprietary long-acting G-CSF ...
... CHENGDU, China, Sept. 17 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, ... and supplier of,modernized traditional Chinese medicine (,TCM,) based in ... call to discuss its fiscal,2009 fourth quarter and full ... 2009. , Interested parties may ...
Cached Biology Technology:Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome 2Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET 2
(Date:8/29/2014)... how the repeated climatic shifts over the last ... genetic diversity, a team of researchers led by ... Carnaval developed a new biodiversity metric called "phylogeographic ... the genetic variation within species is restricted in ... of biology, and 14 other researchers from institutions ...
(Date:8/29/2014)... news release is available in German . ... chemical signals between organisms is considered the oldest form ... interactions between conspecifics, for example, the sexual attraction between ... social responses and to coordinate reproductive behavior in males ... the University of the Algarve in Faro, Portugal, and ...
(Date:8/29/2014)... them, fold them: modern materials that are light, flexible ... artificial skin or electronic paper. , Making such concepts ... a new way of working with copper nanowires and ... , Previous success in the field of ultra-lightweight "aerogel ... gold and silver nanowires. , By turning instead ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Ready for mating at the right time 2Ready for mating at the right time 3Copper shines as flexible conductor 2
... of Pittsburgh of UPMC have discovered a unique population of ... used to treat muscle injuries and diseases such as heart ... muscle tissue, scientists in Children,s Stem Cell Research Center - ... isolated and characterized stem cells taken from blood vessels (known ...
... MOUNTAIN VIEW, Calif., Aug. 13 LaserCard,Corporation (Nasdaq: ... ID credentials,used in biometric identification, today announced the ... Middle Eastern government. A new centralized high-volume ... the optical memory and the eye-readable data of,this ...
... N.Y., Aug. 15 bioMETRX, Inc. (OTC,Bulletin Board: BMRX), ... announced that it is has provided notice to,certain holders ... holders,must surrender said warrants to the company by August ... series B $0.10 warrants that it,has elected to pay ...
Cached Biology News:Pittsburgh scientists identify human source of stem cells with potential to repair muscle 2Pittsburgh scientists identify human source of stem cells with potential to repair muscle 3LaserCard Corporation Announces Expansion of Middle East Project 2LaserCard Corporation Announces Expansion of Middle East Project 3bioMETRX, Inc. Calls Series B Warrants 2
... consists of an anodized aluminum body in ... Compounds embedded in polymerized matrix. It is ... and Synergy Multi-Detection Readers. This multi-functional test ... reducing the need for tedious wet testing. ...
... Safe DNA Gel Stain combo offers these benefits: ... same products separately Offers ... Eliminates risks to yourself, the ... fragments from 100 bp to >30 kb. UltraPure Agarose ...
... economical ICS-90 uses continuous chemical suppression and ... you fast, accurate determinations of common anions ... to operate, quick to equilibrate, and fully ... ICS-90 helps you achieve maximum sample throughput ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
Biology Products: